Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
Conditions: Oral Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma Interventions: Drug: Tislelizumab; Drug: Albumin-Bound Paclitaxel; Drug: Cisplatin Sponsor: Peking University Hospital of Stomatology Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Oral Cancer | Oropharyngeal Cancer | Research